780 related articles for article (PubMed ID: 31741437)
1. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
Thomson SC; Vallon V
Am J Cardiol; 2019 Dec; 124 Suppl 1(Suppl 1):S28-S35. PubMed ID: 31741437
[TBL] [Abstract][Full Text] [Related]
2. The tubular hypothesis of nephron filtration and diabetic kidney disease.
Vallon V; Thomson SC
Nat Rev Nephrol; 2020 Jun; 16(6):317-336. PubMed ID: 32152499
[TBL] [Abstract][Full Text] [Related]
3. Changes in Proximal Tubular Reabsorption Modulate Microvascular Regulation via the TGF System.
Poursharif S; Hamza S; Braam B
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232506
[TBL] [Abstract][Full Text] [Related]
4. Knockout of Na
Song P; Huang W; Onishi A; Patel R; Kim YC; van Ginkel C; Fu Y; Freeman B; Koepsell H; Thomson S; Liu R; Vallon V
Am J Physiol Renal Physiol; 2019 Jul; 317(1):F207-F217. PubMed ID: 31091127
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
[TBL] [Abstract][Full Text] [Related]
6. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
7. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
[TBL] [Abstract][Full Text] [Related]
8. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
Bailey CJ; Day C; Bellary S
Curr Diab Rep; 2022 Jan; 22(1):39-52. PubMed ID: 35113333
[TBL] [Abstract][Full Text] [Related]
9. Role of the macula densa sodium glucose cotransporter type 1-neuronal nitric oxide synthase-tubuloglomerular feedback pathway in diabetic hyperfiltration.
Zhang J; Cai J; Cui Y; Jiang S; Wei J; Kim YC; Chan J; Thalakola A; Le T; Xu L; Wang L; Jiang K; Wang X; Wang H; Cheng F; Buggs J; Koepsell H; Vallon V; Liu R
Kidney Int; 2022 Mar; 101(3):541-550. PubMed ID: 34843754
[TBL] [Abstract][Full Text] [Related]
10. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
Vallon V; Thomson SC
Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
Yakovleva T; Sokolov V; Chu L; Tang W; Greasley PJ; Peilot Sjögren H; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
Diabetes Obes Metab; 2019 Dec; 21(12):2684-2693. PubMed ID: 31423699
[TBL] [Abstract][Full Text] [Related]
13. Effect of renal tubule-specific knockdown of the Na
Onishi A; Fu Y; Darshi M; Crespo-Masip M; Huang W; Song P; Patel R; Kim YC; Nespoux J; Freeman B; Soleimani M; Thomson S; Sharma K; Vallon V
Am J Physiol Renal Physiol; 2019 Aug; 317(2):F419-F434. PubMed ID: 31166707
[TBL] [Abstract][Full Text] [Related]
14. Macula Densa SGLT1-NOS1-Tubuloglomerular Feedback Pathway, a New Mechanism for Glomerular Hyperfiltration during Hyperglycemia.
Zhang J; Wei J; Jiang S; Xu L; Wang L; Cheng F; Buggs J; Koepsell H; Vallon V; Liu R
J Am Soc Nephrol; 2019 Apr; 30(4):578-593. PubMed ID: 30867247
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.
Škrtić M; Cherney DZ
Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):96-103. PubMed ID: 25470017
[TBL] [Abstract][Full Text] [Related]
16. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
[TBL] [Abstract][Full Text] [Related]
17. Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease.
Ravindran S; Munusamy S
J Cell Physiol; 2022 Feb; 237(2):1182-1205. PubMed ID: 34713897
[TBL] [Abstract][Full Text] [Related]
18. Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes.
Gronda EG; Vanoli E; Iacoviello M; Urbinati S; Caldarola P; Colivicchi F; Gabrielli D
Heart Fail Rev; 2023 May; 28(3):723-732. PubMed ID: 35098383
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes.
Solini A; Rossi C; Mazzanti CM; Proietti A; Koepsell H; Ferrannini E
Diabetes Obes Metab; 2017 Sep; 19(9):1289-1294. PubMed ID: 28419670
[TBL] [Abstract][Full Text] [Related]
20. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]